Atrial fibrillation (AF) is the most common arrhythmia in adults, and its incidence and prevalence increase with age. The risk of cognitive impairment and dementia also increases with age, and both AF and cognitive impairment or dementia share important risk factors. In meta-analyses of published studies, AF is associated with a 2.4-fold and 1.4-fold increase in the risk of dementia in patients with or without a history of stroke, respectively. This association is independent of shared risk factors such as hypertension and diabetes mellitus. Neuroimaging has illustrated several potential mechanisms of cognitive decline in patients with AF. AF is associated with increased prevalence of silent cerebral infarcts, and more recent data also suggest an increased prevalence of cerebral microbleeds with AF. AF is also associated with a pro-inflammatory state, and the relationship between AF-induced systemic inflammation and dementia remains to be investigated. Preliminary reports indicate that anticoagulation medication including warfarin can reduce the risk of cognitive impairment in patients with AF. Catheter ablation, increasingly used to maintain sinus rhythm in patients with AF, is associated with the formation of new silent cerebral lesions. The majority of these lesions are not detectable after 1 year, and insufficient data are available to evaluate their effect on cognition. Large prospective studies are urgently needed to confirm the association between AF and dementia, to elucidate the associated mechanisms, and to investigate the effect of anticoagulation and rhythm control on cognition.
Atrial fibrillation is associated with increased risks of dementia and cognitive impairment, independent of history of stroke and other shared risk factors.
Proposed mechanisms of cognitive impairment in atrial fibrillation include cerebral thromboembolism, cerebral hypoperfusion, and cerebral microbleeds.
Anticoagulation might be protective against cognitive impairment in atrial fibrillation, but further prospective studies are needed.
Catheter ablation of atrial fibrillation is associated with new silent cerebral lesions, but the effect on cognitive function is unknown.
Subscribe to Journal
Get full journal access for 1 year
only $4.92 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
Miyasaka, Y. et al. Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence. Circulation 114, 119–125 (2006).
Chugh, S. S. et al. Worldwide epidemiology of atrial fibrillation: a Global Burden of Disease 2010 Study. Circulation 129, 837–847 (2014).
Go, A. S. et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA 285, 2370–2375 (2001).
Hebert, L. E., Weuve, J., Scherr, P. A. & Evans, D. A. Alzheimer disease in the United States estimated using the 2010 census. Neurology 80, 1778–1783 (2013).
Wimo, A., Jonsson, L. & Winblad, B. An estimate of the worldwide prevalence and direct costs of dementia in 2003. Dement. Geriatr. Cogn. Disord. 21, 175–181 (2006).
Wimo, A., Winblad, B. & Jonsson, L. An estimate of the total worldwide societal costs of dementia in 2005. Alzheimers Dement. 3, 81–91 (2007).
Benjamin, E. J. et al. Independent risk factors for atrial fibrillation in a population-based cohort. The Framingham Heart Study. JAMA 271, 840–844 (1994).
Bohm, M. et al. Systolic blood pressure variation and mean heart rate is associated with cognitive dysfunction in patients with high cardiovascular risk. Hypertension 65, 651–661 (2015).
Gudala, K., Bansal, D., Schifano, F. & Bhansali, A. Diabetes mellitus and risk of dementia: A meta-analysis of prospective observational studies. J. Diabetes Investig. 4, 640–650 (2013).
Pendlebury, S. T. & Rothwell, P. M. Prevalence, incidence, and factors associated with pre-stroke and post-stroke dementia: a systematic review and meta-analysis. Lancet Neurol. 8, 1006–1018 (2009).
Wolf, P. A., Abbott, R. D. & Kannel, W. B. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke 22, 983–988 (1991).
Alosco, M. L. et al. Atrial fibrillation exacerbates cognitive dysfunction and cerebral perfusion in heart failure. Pacing Clin. Electrophysiol. 38, 178–186 (2015).
Graff-Radford, J. et al. Atrial fibrillation, cognitive impairment, and neuroimaging. Alzheimers Dement. 12, 391–398 (2016).
Cherubini, A. et al. Underrecognition and undertreatment of dementia in Italian nursing homes. J. Am. Med. Dir. Assoc. 13, 759.e7–759.e13 (2012).
Connolly, A., Gaehl, E., Martin, H., Morris, J. & Purandare, N. Underdiagnosis of dementia in primary care: variations in the observed prevalence and comparisons to the expected prevalence. Aging Ment. Health 15, 978–984 (2011).
Erkinjuntti, T., Ostbye, T., Steenhuis, R. & Hachinski, V. The effect of different diagnostic criteria on the prevalence of dementia. N. Engl. J. Med. 337, 1667–1674 (1997).
Engdahl, J., Andersson, L., Mirskaya, M. & Rosenqvist, M. Stepwise screening of atrial fibrillation in a 75-year-old population: implications for stroke prevention. Circulation 127, 930–937 (2013).
Lin, H. J. et al. Stroke severity in atrial fibrillation. The Framingham Study. Stroke 27, 1760–1764 (1996).
Marini, C. et al. Contribution of atrial fibrillation to incidence and outcome of ischemic stroke: results from a population-based study. Stroke 36, 1115–1119 (2005).
Barba, R. et al. Poststroke dementia: clinical features and risk factors. Stroke 31, 1494–1501 (2000).
Censori, B. et al. Dementia after first stroke. Stroke 27, 1205–1210 (1996).
Inzitari, D. et al. Incidence and determinants of poststroke dementia as defined by an informant interview method in a hospital-based stroke registry. Stroke 29, 2087–2093 (1998).
Zhou, D. H. et al. Study on frequency and predictors of dementia after ischemic stroke: the Chongqing stroke study. J. Neurol. 251, 421–427 (2004).
Kwok, C. S., Loke, Y. K., Hale, R., Potter, J. F. & Myint, P. K. Atrial fibrillation and incidence of dementia: a systematic review and meta-analysis. Neurology 76, 914–922 (2011).
Lees, R. A. et al. Cognitive assessment in stroke: feasibility and test properties using differing approaches to scoring of incomplete items. Int. J. Geriatr. Psychiatry 32, 1072–1078 (2017).
Bunch, T. J. et al. Atrial fibrillation is independently associated with senile, vascular, and Alzheimer’s dementia. Heart Rhythm 7, 433–437 (2010).
Ott, A. et al. Atrial fibrillation and dementia in a population-based study. The Rotterdam Study. Stroke 28, 316–321 (1997).
Marengoni, A., Qiu, C., Winblad, B. & Fratiglioni, L. Atrial fibrillation, stroke and dementia in the very old: a population-based study. Neurobiol. Aging 32, 1336–1337 (2011).
Haring, B. et al. Cardiovascular disease and cognitive decline in postmenopausal women: results from the Women’s Health Initiative Memory study. J. Am. Heart Assoc. 2, e000369 (2013).
Peters, R. et al. Cardiovascular and biochemical risk factors for incident dementia in the Hypertension in the Very Elderly Trial. J. Hypertens. 27, 2055–2062 (2009).
Marzona, I. et al. Increased risk of cognitive and functional decline in patients with atrial fibrillation: results of the ONTARGET and TRANSCEND studies. CMAJ 184, E329–E336 (2012).
Kalantarian, S. et al. Association between atrial fibrillation and silent cerebral infarctions: a systematic review and meta-analysis. Ann. Intern. Med. 161, 650–658 (2014).
Santangeli, P. et al. Atrial fibrillation and the risk of incident dementia: a meta-analysis. Heart Rhythm 9, 1761–1768 (2012).
de Bruijn, R. F. et al. Association between atrial fibrillation and dementia in the general population. JAMA Neurol. 72, 1288–1294 (2015).
Petersen, R. C. et al. Mild cognitive impairment: ten years later. Arch. Neurol. 66, 1447–1455 (2009).
Forti, P. et al. Atrial fibrillation and risk of dementia in non-demented elderly subjects with and without mild cognitive impairment (MCI). Arch. Gerontol. Geriatr. 44 (Suppl. 1), 155–165 (2007).
Di Carlo, A. et al. CIND and MCI in the Italian elderly: frequency, vascular risk factors, progression to dementia. Neurology 68, 1909–1916 (2007).
Thacker, E. L. et al. Atrial fibrillation and cognitive decline: a longitudinal cohort study. Neurology 81, 119–125 (2013).
Tilvis, R. S. et al. Predictors of cognitive decline and mortality of aged people over a 10-year period. J. Gerontol. A. 59, 268–274 (2004).
Healey, J. S. et al. Subclinical atrial fibrillation and the risk of stroke. N. Eng. J. Med. 366, 120–129 (2012).
US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT01938248 (2018).
Ezekowitz, M. D. et al. Silent cerebral infarction in patients with nonrheumatic atrial fibrillation. The veterans affairs stroke prevention nonrheumatic atrial fibrillation investigators. Circulation 92, 2178–2182 (1995).
Wardlaw, J. M. et al. Neuroimaging standards for research into small vessel disease and its contribution to ageing and neurodegeneration. Lancet Neurol. 12, 822–838 (2013).
Vermeer, S. E. et al. Silent brain infarcts and white matter lesions increase stroke risk in the general population: the Rotterdam Scan Study. Stroke 34, 1126–1129 (2003).
Vermeer, S. E. et al. Silent brain infarcts and the risk of dementia and cognitive decline. N. Engl. J. Med. 348, 1215–1222 (2003).
Cha, M. J. et al. Prevalence of and risk factors for silent ischemic stroke in patients with atrial fibrillation as determined by brain magnetic resonance imaging. Am. J. Cardiol. 113, 655–661 (2014).
Chen, L. Y. et al. Atrial fibrillation and cognitive decline-the role of subclinical cerebral infarcts: the atherosclerosis risk in communities study. Stroke 45, 2568–2574 (2014).
Das, R. R. et al. Prevalence and correlates of silent cerebral infarcts in the Framingham offspring study. Stroke 39, 2929–2935 (2008).
Gaita, F. et al. Prevalence of silent cerebral ischemia in paroxysmal and persistent atrial fibrillation and correlation with cognitive function. J. Am. Coll. Cardiol. 62, 1990–1997 (2013).
Kobayashi, A., Iguchi, M., Shimizu, S. & Uchiyama, S. Silent cerebral infarcts and cerebral white matter lesions in patients with nonvalvular atrial fibrillation. J. Stroke Cerebrovasc. Dis. 21, 310–317 (2012).
Longstreth, W. T. Jr et al. Incidence, manifestations, and predictors of brain infarcts defined by serial cranial magnetic resonance imaging in the elderly: the Cardiovascular Health Study. Stroke 33, 2376–2382 (2002).
Marfella, R. et al. Brief episodes of silent atrial fibrillation predict clinical vascular brain disease in type 2 diabetic patients. J. Am. Coll. Cardiol. 62, 525–530 (2013).
Knecht, S. et al. Atrial fibrillation in stroke-free patients is associated with memory impairment and hippocampal atrophy. Eur. Heart J. 29, 2125–2132 (2008).
Greenberg, S. M. et al. Cerebral microbleeds: a guide to detection and interpretation. Lancet Neurol. 8, 165–174 (2009).
Lovelock, C. E. et al. Antithrombotic drug use, cerebral microbleeds, and intracerebral hemorrhage: a systematic review of published and unpublished studies. Stroke 41, 1222–1228 (2010).
Poels, M. M. et al. Cerebral microbleeds are associated with worse cognitive function: the Rotterdam Scan Study. Neurology 78, 326–333 (2012).
van Etten, E. S. et al. Incidence of symptomatic hemorrhage in patients with lobar microbleeds. Stroke 45, 2280–2285 (2014).
Akoudad, S. et al. Association of cerebral microbleeds with cognitive decline and dementia. JAMA Neurol. 73, 934–943 (2016).
Charidimou, A., Kakar, P., Fox, Z. & Werring, D. J. Cerebral microbleeds and recurrent stroke risk: systematic review and meta-analysis of prospective ischemic stroke and transient ischemic attack cohorts. Stroke 44, 995–1001 (2013).
Haji, S. et al. The clinical relevance of cerebral microbleeds in patients with cerebral ischemia and atrial fibrillation. J. Neurol. 263, 238–244 (2016).
Song, T. J. et al. Association of cerebral microbleeds with mortality in stroke patients having atrial fibrillation. Neurology 83, 1308–1315 (2014).
Song, T. J. et al. The frequency of cerebral microbleeds increases with CHADS(2) scores in stroke patients with non-valvular atrial fibrillation. Eur. J. Neurol. 20, 502–508 (2013).
Georgiadis, D. et al. Intracranial microembolic signals in 500 patients with potential cardiac or carotid embolic source and in normal controls. Stroke 28, 1203–1207 (1997).
Haeusler, K. G., Wilson, D., Fiebach, J. B., Kirchhof, P. & Werring, D. J. Brain MRI to personalise atrial fibrillation therapy: current evidence and perspectives. Heart 100, 1408–1413 (2014).
Tsao, C. W. et al. Association of arterial stiffness with progression of subclinical brain and cognitive disease. Neurology 86, 619–626 (2016).
Jefferson, A. L. et al. Lower cardiac index levels relate to lower cerebral blood flow in older adults. Neurology 89, 2327–2334 (2017).
Jefferson, A. L. et al. Relation of left ventricular ejection fraction to cognitive aging (from the Framingham Heart Study). Am. J. Cardiol. 108, 1346–1351 (2011).
Iguchi, Y. et al. Prevalence of atrial fibrillation in community-dwelling Japanese aged 40 years or older in Japan: analysis of 41,436 non-employee residents in Kurashiki-city. Circ. J. 72, 909–913 (2008).
Qiu, C. et al. Heart failure and risk of dementia and Alzheimer disease: a population-based cohort study. Arch. Intern. Med. 166, 1003–1008 (2006).
Roberts, R. O. et al. Cardiac disease associated with increased risk of nonamnestic cognitive impairment: stronger effect on women. JAMA Neurol. 70, 374–382 (2013).
Tremblay-Gravel, M. et al. Blood pressure and atrial fibrillation: a combined AF-CHF and AFFIRM analysis. J. Cardiovasc. Electrophysiol. 26, 509–514 (2015).
Hailpern, S. M., Melamed, M. L., Cohen, H. W. & Hostetter, T. H. Moderate chronic kidney disease and cognitive function in adults 20 to 59 years of age: Third National Health and Nutrition Examination Survey (NHANES III). J. Am. Soc. Nephrol. 18, 2205–2213 (2007).
Liao, J. N. et al. Incidence and risk factors for new-onset atrial fibrillation among patients with end-stage renal disease undergoing renal replacement therapy. Kidney Int. 87, 1209–1215 (2015).
Mukamal, K. J. et al. Prospective study of alcohol consumption and risk of dementia in older adults. JAMA 289, 1405–1413 (2003).
Mukamal, K. J., Tolstrup, J. S., Friberg, J., Jensen, G. & Gronbaek, M. Alcohol consumption and risk of atrial fibrillation in men and women: the Copenhagen City Heart Study. Circulation 112, 1736–1742 (2005).
Gami, A. S. et al. Obstructive sleep apnea, obesity, and the risk of incident atrial fibrillation. J. Am. Coll. Cardiol. 49, 565–571 (2007).
Spira, A. P. et al. Sleep-disordered breathing and cognition in older women. J. Am. Geriatr. Soc. 56, 45–50 (2008).
Hu, Y. F., Chen, Y. J., Lin, Y. J. & Chen, S. A. Inflammation and the pathogenesis of atrial fibrillation. Nat. Rev. Cardiol. 12, 230–243 (2015).
Barber, M. et al. Dementia in subjects with atrial fibrillation: hemostatic function and the role of anticoagulation. J. Thromb. Haemost. 2, 1873–1878 (2004).
Austin, B. P. et al. Effects of hypoperfusion in Alzheimer’s disease. J. Alzheimers Dis. 26 (Suppl. 3), 123–133 (2011).
de Bruijn, R. F. et al. Subclinical cardiac dysfunction increases the risk of stroke and dementia: the Rotterdam Study. Neurology 84, 833–840 (2015).
Lavy, S. et al. Effect of chronic atrial fibrillation on regional cerebral blood flow. Stroke 11, 35–38 (1980).
Gardarsdottir, M. et al. Atrial fibrillation is associated with decreased total cerebral blood flow and brain perfusion. Europace 20, 1252–1258 (2017).
Shi, Y. et al. Cerebral blood flow in small vessel disease: a systematic review and meta-analysis. J. Cereb. Blood Flow Metab. 36, 1653–1667 (2016).
Charidimou, A., Shakeshaft, C. & Werring, D. J. Cerebral microbleeds on magnetic resonance imaging and anticoagulant-associated intracerebral hemorrhage risk. Front. Neurol. 3, 133 (2012).
Benedictus, M. R. et al. Prognostic factors for cognitive decline after intracerebral hemorrhage. Stroke 46, 2773–2778 (2015).
Garcia, P. Y. et al. Cognitive impairment and dementia after intracerebral hemorrhage: a cross-sectional study of a hospital-based series. J. Stroke Cerebrovasc. Dis. 22, 80–86 (2013).
Horstmann, S. et al. Prevalence of atrial fibrillation and association of previous antithrombotic treatment in patients with cerebral microbleeds. Eur. J. Neurol. 22, 1355–1362 (2015).
Orken, D. N. et al. New cerebral microbleeds in ischemic stroke patients on warfarin treatment: two-year follow-up. Clin. Neurol. Neurosurg. 115, 1682–1685 (2013).
Lei, C. et al. Association between cerebral microbleeds and cognitive function: a systematic review. J. Neurol. Neurosurg. Psychiatry 84, 693–697 (2013).
Selim, M. & Diener, H. C. Atrial fibrillation and microbleeds. Stroke 48, 2660–2664 (2017).
Chao, T. F. et al. Plasma asymmetric dimethylarginine and adverse events in patients with atrial fibrillation referred for coronary angiogram. PLoS ONE 8, e71675 (2013).
Conway, D. S., Pearce, L. A., Chin, B. S., Hart, R. G. & Lip, G. Y. Prognostic value of plasma von Willebrand factor and soluble P-selectin as indices of endothelial damage and platelet activation in 994 patients with nonvalvular atrial fibrillation. Circulation 107, 3141–3145 (2003).
Lip, G. Y., Patel, J. V., Hughes, E. & Hart, R. G. High-sensitivity C-reactive protein and soluble CD40 ligand as indices of inflammation and platelet activation in 880 patients with nonvalvular atrial fibrillation: relationship to stroke risk factors, stroke risk stratification schema, and prognosis. Stroke 38, 1229–1237 (2007).
Roldan, V. et al. High sensitivity cardiac troponin T and interleukin-6 predict adverse cardiovascular events and mortality in anticoagulated patients with atrial fibrillation. J. Thromb. Haemost. 10, 1500–1507 (2012).
Enciu, A. M. & Popescu, B. O. Is there a causal link between inflammation and dementia? Biomed. Res. Int. 2013, 316495 (2013).
Sidorova, T. N. et al. Reactive γ-ketoaldehydes promote protein misfolding and preamyloid oligomer formation in rapidly-activated atrial cells. J. Mol. Cell. Cardiol. 79, 295–302 (2015).
Boutaud, O., Montine, T. J., Chang, L., Klein, W. L. & Oates, J. A. PGH2-derived levuglandin adducts increase the neurotoxicity of amyloid beta1-42. J. Neurochem. 96, 917–923 (2006).
January, C. T. et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society. Circulation 130, e199–e267 (2014).
Jacobs, V., Graves, K. G. & Bunch, T. J. Anticoagulant use in atrial fibrillation and risk of dementia: review of contemporary knowledge. Expert Rev. Cardiovasc. Ther. 15, 897–903 (2017).
Madhavan, M. et al. Efficacy of warfarin anticoagulation and incident dementia in a community based cohort of atrial fibrillation. Mayo Clin. Proc. 93, 145–154 (2018).
Mavaddat, N. et al. Warfarin versus aspirin for prevention of cognitive decline in atrial fibrillation: randomized controlled trial (Birmingham Atrial Fibrillation Treatment of the Aged Study). Stroke 45, 1381–1386 (2014).
Moffitt, P., Lane, D. A., Park, H., O’Connell, J. & Quinn, T. J. Thromboprophylaxis in atrial fibrillation and association with cognitive decline: systematic review. Age Ageing 45, 767–775 (2016).
Flaker, G. C. et al. Cognitive function and anticoagulation control in patients with atrial fibrillation. Circ. Cardiovasc. Qual. Outcomes 3, 277–283 (2010).
Jacobs, V. et al. Time outside of therapeutic range in atrial fibrillation patients is associated with long-term risk of dementia. Heart Rhythm 11, 2206–2213 (2014).
Jacobs, V. et al. Percent time with a supratherapeutic INR in atrial fibrillation patients also using an antiplatelet agent is associated with long-term risk of dementia. J. Cardiovasc. Electrophysiol. 26, 1180–1186 (2015).
Reynolds, M. W. et al. Warfarin anticoagulation and outcomes in patients with atrial fibrillation: a systematic review and metaanalysis. Chest 126, 1938–1945 (2004).
O’ Donnell, M. J. et al. Effect of apixaban on brain infarction and microbleeds: AVERROES-MRI assessment study. Am. Heart J. 178, 145–150 (2016).
Granger, C. B. et al. Apixaban versus warfarin in patients with atrial fibrillation. N. Engl. J. Med. 365, 981–992 (2011).
Connolly, S. J. et al. Dabigatran versus warfarin in patients with atrial fibrillation. N. Engl. J. Med. 361, 1139–1151 (2009).
Patel, M. R. et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N. Engl. J. Med. 365, 883–891 (2011).
Jacobs, V. et al. Long-term population-based cerebral ischemic event and cognitive outcomes of direct oral anticoagulants compared with warfarin among long-term anticoagulated patients for atrial fibrillation. Am. J. Cardiol. 118, 210–214 (2016).
US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT02387229 (2018).
US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT01994265 (2017).
Reddy, V. Y. et al. 5-Year outcomes after left atrial appendage closure: from the PREVAIL and PROTECT AF trials. J. Am. Coll. Cardiol. 70, 2964–2975 (2017).
Van Gelder, I. C. et al. A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N. Engl. J. Med. 347, 1834–1840 (2002).
Chung, M. K. et al. Functional status in rate- versus rhythm-control strategies for atrial fibrillation: results of the Atrial Fibrillation Follow-Up Investigation of Rhythm Management (AFFIRM) Functional Status Substudy. J. Am. Coll. Cardiol. 46, 1891–1899 (2005).
US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT01288352 (2017).
Cappato, R. et al. Updated worldwide survey on the methods, efficacy, and safety of catheter ablation for human atrial fibrillation. Circ. Arrhythm. Electrophysiol. 3, 32–38 (2010).
Deneke, T. et al. Postablation asymptomatic cerebral lesions: long-term follow-up using magnetic resonance imaging. Heart Rhythm 8, 1705–1711 (2011).
Gaita, F. et al. Incidence of silent cerebral thromboembolic lesions after atrial fibrillation ablation may change according to technology used: comparison of irrigated radiofrequency, multipolar nonirrigated catheter and cryoballoon. J. Cardiovasc. Electrophysiol. 22, 961–968 (2011).
Gaita, F. et al. Radiofrequency catheter ablation of atrial fibrillation: a cause of silent thromboembolism? Magnetic resonance imaging assessment of cerebral thromboembolism in patients undergoing ablation of atrial fibrillation. Circulation 122, 1667–1673 (2010).
Herrera Siklody, C. et al. Incidence of asymptomatic intracranial embolic events after pulmonary vein isolation: comparison of different atrial fibrillation ablation technologies in a multicenter study. J. Am. Coll. Cardiol. 58, 681–688 (2011).
Martinek, M. et al. Asymptomatic cerebral lesions during pulmonary vein isolation under uninterrupted oral anticoagulation. Europace 15, 325–331 (2013).
Scaglione, M. et al. Impact of ablation catheter irrigation design on silent cerebral embolism after radiofrequency catheter ablation of atrial fibrillation: results from a pilot study. J. Cardiovasc. Electrophysiol. 23, 801–805 (2012).
Neumann, T. et al. MEDAFI-Trial (micro-embolization during ablation of atrial fibrillation): comparison of pulmonary vein isolation using cryoballoon technique versus radiofrequency energy. Europace 13, 37–44 (2011).
Di Biase, L. et al. Does periprocedural anticoagulation management of atrial fibrillation affect the prevalence of silent thromboembolic lesion detected by diffusion cerebral magnetic resonance imaging in patients undergoing radiofrequency atrial fibrillation ablation with open irrigated catheters? Results from a prospective multicenter study. Heart Rhythm 11, 791–798 (2014).
Zhao, Y. et al. New oral anticoagulants compared to warfarin for perioperative anticoagulation in patients undergoing atrial fibrillation catheter ablation: a meta-analysis of continuous or interrupted new oral anticoagulants during ablation compared to interrupted or continuous warfarin. J. Interv. Card. Electrophysiol. 48, 267–282 (2017).
US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT02227550 (2017).
Ichiki, H. et al. Incidence of asymptomatic cerebral microthromboembolism after atrial fibrillation ablation guided by complex fractionated atrial electrogram. J. Cardiovasc. Electrophysiol. 23, 567–573 (2012).
Madhavan, M., Govil, S. R. & Asirvatham, S. J. Signals. Circ. Arrhythm. Electrophysiol. 5, 2–4 (2012).
Nakamura, K. et al. Silent cerebral ischemic lesions after catheter ablation of atrial fibrillation in patients on 5 types of periprocedural oral anticoagulation-predictors of diffusion-weighted imaging-positive lesions and follow-up magnetic resonance imaging. Circ. J. 80, 870–877 (2016).
Rillig, A. et al. Incidence and long-term follow-up of silent cerebral lesions after pulmonary vein isolation using a remote robotic navigation sytem as compared to manual ablation. Circ. Arrhythm Electrophysiol. 5, 15–21 (2012).
Haines, D. E. et al. Microembolism and catheter ablation II: effects of cerebral microemboli injection in a canine model. Circ. Arrhythm. Electrophysiol. 6, 23–30 (2013).
Medi, C. et al. Subtle post-procedural cognitive dysfunction after atrial fibrillation ablation. J. Am. Coll. Cardiol. 62, 531–539 (2013).
von Bary, C. et al. Silent cerebral events as a result of left atrial catheter ablation do not cause neuropsychological sequelae — a MRI-controlled multicenter study. J. Interv. Card. Electrophysiol. 43, 217–226 (2015).
Kokmen, E., Whisnant, J. P., O’Fallon, W. M., Chu, C. P. & Beard, C. M. Dementia after ischemic stroke: a population-based study in Rochester, Minnesota (1960–1984). Neurology 46, 154–159 (1996).
Bunch, T. J. et al. Atrial fibrillation ablation patients have long-term stroke rates similar to patients without atrial fibrillation regardless of CHADS2 score. Heart Rhythm 10, 1272–1277 (2013).
van Veluw, S. J. et al. Detection, risk factors, and functional consequences of cerebral microinfarcts. Lancet Neurol. 16, 730–740 (2017).
van Kuilenburg, J. et al. Persisting thrombin activity in elderly patients with atrial fibrillation on oral anticoagulation is decreased by anti-inflammatory therapy with intensive cholesterol-lowering treatment. J. Clin. Lipidol. 5, 273–280 (2011).
Lappegard, K. T. et al. Improved neurocognitive functions correlate with reduced inflammatory burden in atrial fibrillation patients treated with intensive cholesterol lowering therapy. J. Neuroinflamm. 10, 78 (2013).
Dublin, S. et al. Atrial fibrillation and risk of dementia: a prospective cohort study. J. Am. Geriatr. Soc. 59, 1369–1375 (2011).
Elias, M. F. et al. Atrial fibrillation is associated with lower cognitive performance in the Framingham offspring men. J. Stroke Cerebrovasc. Dis. 15, 214–222 (2006).
Park, H., Hildreth, A., Thomson, R. & O’Connell, J. Non-valvular atrial fibrillation and cognitive decline: a longitudinal cohort study. Age Ageing 36, 157–163 (2007).
Rastas, S. et al. Atrial fibrillation, stroke, and cognition: a longitudinal population-based study of people aged 85 and older. Stroke 38, 1454–1460 (2007).
Li, J. et al. Vascular risk factors promote conversion from mild cognitive impairment to Alzheimer disease. Neurology 76, 1485–1491 (2011).
Jozwiak, A., Guzik, P., Mathew, A., Wykretowicz, A. & Wysocki, H. Association of atrial fibrillation and focal neurologic deficits with impaired cognitive function in hospitalized patients >or =65 years of age. Am. J. Cardiol. 98, 1238–1241 (2006).
Alonso, A. et al. Correlates of dementia and mild cognitive impairment in patients with atrial fibrillation: the Atherosclerosis Risk in Communities Neurocognitive Study (ARIC-NCS). J. Am. Heart Assoc. 6, e006014 (2017).
Nishtala, A. et al. Atrial fibrillation and cognitive decline in the Framingham Heart Study. Heart Rhythm 15, 166–172 (2018).
Nature Reviews Cardiology thanks S. Seshadri, M. A. Ikram, and the other anonymous reviewer(s) for their contribution to the peer review of this work.
J.P.P. has received support from ARCA biopharma, Boston Scientific, GE Healthcare, and Johnson & Johnson/Janssen Scientific Affairs and from consultancies to Forest Laboratories, Janssen Scientific Affairs, Medtronic, Pfizer/Bristol Myers Squibb, and Spectranetics. B.J.G. receives modest support for consulting provided to Janssen Pharmaceuticals and Bristol-Myers Squibb. The other authors declare no competing interests.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Madhavan, M., Graff-Radford, J., Piccini, J.P. et al. Cognitive dysfunction in atrial fibrillation. Nat Rev Cardiol 15, 744–756 (2018). https://doi.org/10.1038/s41569-018-0075-z
Seminars in Neurology (2021)
Association of Risk of Dementia With Direct Oral Anticoagulants Versus Warfarin Use in Patients With Non-valvular Atrial Fibrillation: A Systematic Review and Meta-analysis
Journal of Cardiovascular Pharmacology (2021)
Lower Risk of Dementia in Patients With Atrial Fibrillation Taking Non‐Vitamin K Antagonist Oral Anticoagulants: A Nationwide Population‐Based Cohort Study
Journal of the American Heart Association (2021)
Mayo Clinic Proceedings (2021)
Office, central and ambulatory blood pressure for predicting incident atrial fibrillation in older adults
Journal of Hypertension (2021)